ALUMINUM-BASED ADJUVANTS ARE BACK IN THE SPOTLIGHT!
OUR ANALYSIS OF THE MISLEADINGLY REASSURING STUDY BY DOYON-PLOURDE ET AL. A NEW STUDY ON ALUMINUM-BASED ADJUVANTS

On May 6, 2026, a new article was published to reassure the public (and the markets, no doubt) about aluminum-based adjuvants (ABAs). This time, it’s the Centre for Immunization, Surveillance, and Programs—Public Health Agency of Canada taking the lead, with this article published by the BMJ: “Aluminum adjuvants in vaccines and potential health effects: systematic review.”

 

When it comes to a major public health issue, you should never settle for just reading the title or the abstract. You need to read the entire publication, read the reviewers’ comments, and read the comments—including the quick responses—posted by expert readers to the editorial team and published online by the publisher. Let us take you through this in broad strokes.

OUR ANALYSIS OF THIS STUDY ON ALUMINUM-BASED ADJUVANTS

1. The authors are employees of a Canadian government agency. They did not deem it necessary to consult—or involve—international scientists specializing in the subject of their research.
2. They chose to focus exclusively on human studies. No animal toxicology or pharmacokinetic data. No data from in vitro experiments (on cells, for example). A clever way to avoid controversial topics… This is what is known as “looking under the streetlight”—that is, never shedding light on the gray areas.
3. The result is therefore fitting: a self-serving argument asserting that “Current data do not allow for establishing a causal link between vaccines containing an aluminum-based adjuvant and serious or long-term adverse health effects.”
4. The publication was immediately picked up by the press, mostly with the same headline: “Aluminum in vaccines: end of the debate?” Surprising, isn’t it?
5. Conclusion: mission accomplished—a public agency has once again come to the rescue of aluminum-based vaccine manufacturers, and the mainstream media (by analogy to conventional agriculture) has followed suit. But beware: citizens are becoming less and less gullible!

THE STREETLIGHT EFFECT: “ALUMINUM-CONTAINING VACCINES ARE SAFE…”

The Public Health Agency of Canada aimed to “conduct a systematic review and critical appraisal of human evidence on the potential health effects of aluminum-adjuvanted vaccines. ”

It nevertheless notes that “Although histological deposits of MFM have been identified in a subset of individuals biopsied for musculoskeletal symptoms following vaccination, the available data do not establish how, if at all, these local aluminum inclusions are related to systemic symptoms. ”

A terrible admission of irrelevance in the choice to limit oneself to only specific human data! For there is a body of solid evidence regarding the toxicity of aluminum-based adjuvants (ABAs) and their persistence in the body. Animal studies (mice, sheep) demonstrate the fate of the aluminum adjuvant in the body, as well as the consequences on behavior.
Deliberately choosing to ignore them under the pretext of focusing solely on certain epidemiological data is an anti-scientific approach.

Why forego expertise on aluminum?

Public Health Canada staff conducted their literature review without ever consulting international experts on the toxicity of either aluminum or ABAs.
To our knowledge, four of these excluded experts sent a highly critical Rapid Response to the editor, which we share with our readers in our full report (currently only available in French).
The response from Prof. Gøtzsche (one of the founders of the world-renowned Cochrane Collaboration) was published by the BMJ, but the other three were not: that of Dr. Crépeaux, an ABA specialist and reviewer of the publication who recommended its rejection due to its inherent weaknesses; that of Prof. Exley, the world’s leading expert on aluminum toxicity; and that of Patrick McGuinness, a data analysis specialist. Does the BMJ fear the very debate it claims to promote?

And despite all these limitations, another reality emerges…

This Canadian literature review provides no evidence of the safety of ABAs.

• The authors acknowledge the presence of persistent MFM (aluminum-containing) lesions at injection sites for months or even years.
• The authors also admit that “the findings regarding MFM and ASD derived from these studies should be considered hypothesis-generating.”
• Will the Public Health Agency of Canada, and its counterparts in other countries, follow these recommendations and explore these hypotheses by funding the work of competent and ethical researchers?
  

  For this article does not demonstrate the absence of risk associated with ASDs. Rather, it demonstrates the lack of studies (particularly epidemiological ones) capable of properly investigating certain rare, delayed, neuroimmune, or developmental effects.

 

THE MAINSTREAM MEDIA FOLLOWS SUIT

The study’s conclusions—“Current data do not allow for the establishment of a causal link between vaccines containing an aluminum-based adjuvant and serious or long-term adverse health effects”—are reported by the press without any critical analysis:

Pourquoi Docteur, May 7: « Aluminum in vaccines: no link found with autism »
Dauphiné Libéré, May 13: « Aluminum in vaccines and serious illnesses: end of the debate? »
Le Progrès, May 13: « Aluminum in vaccines and serious illnesses: end of the debate? »
JIM, May 21: « Aluminum in vaccines: a systematic review offers reassurance »
Futura-Sciences, May 26: « Aluminum in vaccines: end of the controversy? »

These are either reprints of news dispatches or press releases issued by an influencer (public or private). They are not scientific articles, but rather communication efforts designed to “reassure” the public.

 

The authors of these two scientific literature reviews are behaving in a deeply disrespectful manner toward the public, which expects integrity and loyalty from the scientists whose work it funds.
Has the concept of the common good lost all meaning?